Please ensure Javascript is enabled for purposes of website accessibility

This Tech Dinosaur Just Took a Game-Changing Step in Healthcare

By Jason Hawthorne - Apr 10, 2021 at 6:57AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The future of computing is now.

Quantum physics sounds like science fiction to most people. That's because until recently, it has been largely theoretical. It describes the behavior of atoms and fundamental particles, and asserts that these can be in two states at once or somehow entangled with one another despite being separated by a vast distance.

Quantum computing uses its "spooky" principles to tackle problems that are too complex for traditional computing. While traditional computers represent every operation in binary digits, or bits (zeros and ones), qubits (quantum bits) offer an infinitely faster method since they have no fixed state. Tech giants like Microsoft (MSFT -0.47%) and Alphabet (GOOG -1.53%) (GOOGL -1.51%) have been racing to build useful quantum computers, but IBM (IBM 0.32%) just signed a partnership that could vault it to the top of the pack in the healthcare space.

A person standing in a room with every surface covered in screens of data.

Image source: Getty Images.

The deal

IBM agreed to a 10-year tie-up with the Cleveland Clinic as its official partner for artificial intelligence (AI) and quantum computing. In the deal, the nonprofit academic medical center would have the first on-premise quantum computing system in the private sector. That's no small feat considering the system requires near absolute zero temperatures (about negative 469 degrees Fahrenheit) and a continuous supply of helium and liquid nitrogen to operate.

The goal is to use the computing power to generate and analyze data in areas like genomics, population health, and chemical and drug discovery. As an example, it currently takes about 15 years  for a new therapy to be developed and tested before it gets to patients. This technology could reduce that to weeks if not days. It won't be the first time the two institutions have partnered on AI. They previously worked together using IBM's Watson to assist physicians and help guide care across a patient's entire journey through the healthcare system.

The possibilities

To understand why it is such a leap forward, it's helpful to find a clear-cut comparison. University of Virginia researchers recently deployed a "toy", or simplified, problem on an IBM quantum system to classify genomic data. If they used all four DNA building blocks to perform the classification (A,G,C, and T), a traditional computer would execute three billion operations to perform the task. Using a quantum computer, it took 32. In a similar jaw-dropping display in 2019, Google's quantum computer was able to complete a task in 200 seconds that  would have taken an estimated 10,000 years on a traditional computer. Quantum computing controls the atoms and fundamental particles in the system, assigning identity, like a probability, rather than a zero or one. Not only does that make it more efficient, it means natural systems can be modeled more accurately.

It could enable super-fast drug development with clinical trials conducted on virtual humans, instantaneous genome sequencing for a personalized prescription, or the creation of comprehensive electronic health records (EHRs) using every piece of relevant data to generate truly predictive care. It would even be possible to search every molecule and simulate its interaction with different types of cells to identify a cure for a disease. There is already precedent.

In 2015, AI-based firm Atomwise took four months using artificial intelligence to search existing drugs and identify two as potential candidates to treat Ebola. Imagine if quantum computing could have been used for a COVID vaccine and tested on tens of thousands of virtual humans in a matter of days. Moderna's COVID vaccine had been designed by mid-January of 2020. It was the clinical trial that took ten months. With quantum computing, we might have the vaccine for the next pandemic the same week it is declared.

The future

Peter Chapman, the former director of engineering for Amazon Prime and current CEO of IonQ (a Microsoft partner), believes quantum computing will also produce a human-like AI. In medicine for example, there is no way a doctor can have full knowledge of the latest information available, but a quantum computer could sift through all the medical studies at once and offer support for any decision a doctor has to make. 

Whether IBM commercializes it first or not, it appears the future of computing is quantum. Despite the technical challenges of deploying a quantum system, the economic potential is too large not to solve them, and advances keep coming. Last year, a team in China claimed supremacy with a system that is 10 billion times faster than the one Google highlighted in 2019. 

For investors, there are a growing number of ways to invest in the potential of quantum computing. Aside from the technology giants, Honeywell (HON -0.90%) has also promoted its quantum system, and IonQ is planning to go public through a special purpose acquisition company (SPAC) called DMY Technology Group (DMYI). It's hard to say which company will ultimately succeed. IBM's relationship with the Cleveland Clinic and its on-site quantum system give it a leg up in accessing large amounts of data and rolling out applications. As Tesla has shown with autonomous driving, a data advantage in artificial intelligence applications can compound very quickly, rendering competitors mere technological footnotes.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool’s board of directors. Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Amazon, Microsoft, and Tesla. The Motley Fool recommends the following options: long January 2022 $1920.0 calls on Amazon and short January 2022 $1940.0 calls on Amazon. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

International Business Machines Corporation Stock Quote
International Business Machines Corporation
IBM
$137.00 (0.32%) $0.44
Microsoft Corporation Stock Quote
Microsoft Corporation
MSFT
$290.72 (-0.47%) $-1.37
Alphabet Inc. Stock Quote
Alphabet Inc.
GOOGL
$119.86 (-1.51%) $-1.84
Tesla, Inc. Stock Quote
Tesla, Inc.
TSLA
$906.48 (-1.44%) $-13.21
Amazon.com, Inc. Stock Quote
Amazon.com, Inc.
AMZN
$141.20 (-2.47%) $-3.58
Honeywell International Inc. Stock Quote
Honeywell International Inc.
HON
$201.83 (-0.90%) $-1.84
Alphabet Inc. Stock Quote
Alphabet Inc.
GOOG
$120.63 (-1.53%) $-1.88
dMY Technology Group, Inc. III Stock Quote
dMY Technology Group, Inc. III
DMYI

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.